News

This month's cover feature delves into the new applications and use of AI in dermatology and considers how AI can support clinicians rather than hinder them.

November is Hyperhidrosis Awareness Month, and dermatology clinicians are gearing up for another month of raising awareness to improve patient outcomes.

The PC Project provides patients with access to the International PC Research Registry for clinical help with their rare and painful skin condition.

Aaron Farberg, MD, and Shanna Miranti, MPAS, PA-C, discuss the upcoming approvals of nivolumab and IDP-126.

AbbVie announced the 24- and 52-week data at EADV 2023.

Patients and their families experienced significant improvements to well-being with tildrakizumab use in as little as 16 weeks.

The impact of acne conglobata on individuals underscores the crucial role dermatologists play in providing effective diagnosis, treatment, and emotional support.

New data from ADORING 1 and ADORING 2 show a rapid reduction in pruritus relief as early as 24 hours after the first application.

Longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation.

Clinical response was maintained at 73.2% for PASI-75 in POETYK PSO long-term extension trial.

A European Academy of Dermatology and Venereology study explored the pathway from dermatologic consult to diagnosis to treatment and outcomes in the health care system.

Sexual and gender minority patients with chronic inflammatory skin diseases may be disproportionately influenced by cost and noncost obstacles to health care.

Dermatologist Diego Ruiz Dasilva, MD, FAAD, and a patient with atopic dermatitis discuss the patient journey from initial symptoms to diagnosis to treatment selection.

Kyverna Therapeutics can now initiate its phase 1/2 open-label, multicenter study of KYV-101.

The data presents compelling evidence for the sustained efficacy and safety of the oral JAK1 inhibitor in the treatment of moderate to severe atopic dermatitis over an extended 140-week period.

Experts discuss the treatment landscape of generalized pustular psoriasis as well as review difficult cases of GPP.

The impact begins in utero, with the diet and health of the mother playing a key role in the potential for a child to develop diseases.

This week’s collection of the latest dermatologic studies covers the incidence of keratinocyte carcinomas, upadacitinib used to treat discoid lupus erythematosus, considerations about hair camouflage for Black women with alopecia, and parent perspectives of infants undergoing surgical treatment for congenital melanocytic nevus.

Kristina Collins, MD, delves into the importance of being present in the moments you have control over and making self-care a priority on the road.

This World Mental Health Day, Zoe Diana Draelos, MD, discusses the importance of prioritizing physician well-being in order to prevent burnout, or as Draelos instead refers to it, "stasis."

In a population-based cohort study, researchers explored the mortality of vitiligo as there is limited information about the risks of mortality among these patients.

In this week’s Pointers With Portela, the 208SkinDoc reviews his tips for treating blackheads and whiteheads, as well as recommended products.

AD in the elderly demands specialized attention, considering the unique challenges presented by concurrent skin conditions and underlying systemic diseases.

This World Mental Health Day, Dermatology Times is reviewing the important and often comorbid mental health concerns linked to common dermatologic conditions.

The grant will go toward supporting the group's project, "Atopic Dermatitis is More Than a Skin Disease: Raising Awareness and Improving Care."

The October issue of Dermatology Times spotlights numerous awareness campaigns and their impact on improving and enhancing patient care.

Greater treatment costs are associated with more advanced stages of melanoma, particularly due to increasing prices of treatments.

Click here to answer this week's skin cancer poll.

A BLA is expected to be submitted by Q3 of 2024.

Protagonist Therapeutics has just announced the company's eligibility to receive $60 million of milestone payments for JNJ-2113 to enter into clinical development programs led by Janssen.